Article Information
History
- October 24, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Anna Brandt1,
- Konrad Klinghammer2,
- Christoph Schultheiss1,3,
- Lisa Paschold4,
- Claudia Wickenhauser5,
- Marcus Bauer5,
- Anna Bergqvist6,
- Dennis Hahn7,
- Philippe Schafhausen8,
- Mareike Tometten9,
- Markus Blaurock10,
- Henrike Barbara Zech11,
- Chia-Jung Busch10,
- Andreas Dietz12,
- Urs Müller-Richter13,
- Jürgen Alt14,
- Andreas Boehm15,
- Simone Kowoll16,
- Jörg Steighardt16,
- Alexander Lasch16,
- Ingunn Hagen Westgaard6,
- Marita Westhrin6,
- Alexander Stein17,
- Axel Hinke18 and
- Mascha Binder1,3,*
- 1Division of Medical Oncology, University Hospital Basel, Basel, Switzerland
- 2Department of Hematology and Oncology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- 3Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland
- 4Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
- 5Institute of Pathology, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
- 6Ultimovacs ASA, Oslo, Norway
- 7Klinikum Stuttgart, Stuttgart, Germany; Dept. of Hematology, Oncology, Stem-Cell Transplantation and Palliative Care
- 8Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 9Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
- 10Department of Otorhinolaryngology, Head and Neck Surgery, University Medicine Greifswald, Greifswald, Germany
- 11Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 12Department of Otolaryngology, Head and Neck Surgery, University of Leipzig, Leipzig, Germany
- 13University Hospital Würzburg, Bavarian Cancer Research Center (BZKF), Würzburg, Germany
- 14Department of Internal Medicine III (Hematology, Oncology), University Medical Center Mainz, Mainz, Germany
- 15Department of Otorhinolaryngology, St. Georg Hospital, Leipzig, Germany
- 16Coordination Center for Clinical Trials, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
- 17Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany
- 18Clinical Cancer Research Consulting (CCRC), Düsseldorf, Germany
- ↵*Corresponding author:
Mascha Binder, Medical Oncology, University Hospital Basel, Switzerland, mascha.binder{at}usb.de
Posted October 24, 2024.
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
